UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Gefitinib and Erlotinib in Metastatic Non‐Small Cell Lung Cancer: A Meta‐Analysis of Toxicity and Efficacy of Randomized Clinical Trials

The oncologist (Dayton, Ohio), 2015-04, Vol.20 (4), p.400-410

2015

Volltextzugriff (PDF)

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Cell metabolism, 2021-01, Vol.33 (1), p.78-93.e7

2021

Volltextzugriff (PDF)

Proteasome inhibitors in cancer therapy

Nature reviews. Clinical oncology, 2017-07, Vol.14 (7), p.417-433

2017

Volltextzugriff (PDF)

Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial

Nature communications, 2024-08, Vol.15 (1), p.6874-15, Article 6874

2024

Volltextzugriff (PDF)

Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms

International journal of molecular sciences, 2022-11, Vol.23 (21), p.13427

2022

Volltextzugriff (PDF)

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma

Haematologica (Roma), 2020-05, Vol.105 (5), p.e242-e245

2020

Volltextzugriff (PDF)

The role of soluble B cell maturation antigen as a biomarker in multiple myeloma

Leukemia & lymphoma, 2023-01, Vol.64 (2), p.261-272

2023

Volltextzugriff (PDF)

Carfilzomib boosted combination therapy for relapsed multiple myeloma

OncoTargets and therapy, 2017-01, Vol.10, p.895-907

2017

Volltextzugriff (PDF)

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis

Cancer medicine (Malden, MA), 2023-07, Vol.12 (13), p.14293-14304

2023

Volltextzugriff (PDF)

What to do with minimal residual disease testing in myeloma

Hematology, 2019-12, Vol.2019 (1), p.137-141

Manasanch, Elisabet E

2019

Volltextzugriff (PDF)

High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications

Best practice & research. Clinical haematology, 2020-03, Vol.33 (1), p.101152-101152, Article 101152

2020

Volltextzugriff (PDF)

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis

Blood advances, 2019-08, Vol.3 (15), p.2400-2408

2019

Volltextzugriff (PDF)

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma

Leukemia & lymphoma, 2014-08, Vol.55 (8), p.1707-1714

2014

Volltextzugriff (PDF)

Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma

NPJ precision oncology, 2023-09, Vol.7 (1), p.95-95, Article 95

2023

Volltextzugriff (PDF)

Response-adapted approach in newly diagnosed myeloma: when less is at least equal

Leukemia & lymphoma, 2022-07, Vol.63 (9), p.2021-2022

2022

Volltextzugriff (PDF)

Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up

Blood cancer journal (New York), 2021-02, Vol.11 (2), p.17-17, Article 17

2021

Volltextzugriff (PDF)

The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact

Expert review of hematology, 2021-12, Vol.14 (12), p.1059-1069

2021

Volltextzugriff (PDF)

Myc is also the bad guy in myeloma

Leukemia & lymphoma, 2016-11, Vol.57 (11), p.2485-2486

Manasanch, Elisabet E.

2016

Volltextzugriff (PDF)

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Nature communications, 2021-03, Vol.12 (1), p.1861-1861, Article 1861

2021

Volltextzugriff (PDF)

Recommend maintenance therapy with lenalidomide in multiple myeloma

Seminars in oncology, 2016-12, Vol.43 (6), p.712-713

Manasanch, Elisabet E

2016

Volltextzugriff (PDF)

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials

Haematologica (Roma), 2014-12, Vol.99 (12), p.1769-1771

2014

Volltextzugriff (PDF)

Pre-transplant bone marrow myeloma cells: less is better

Leukemia & lymphoma, 2017-02, Vol.58 (2), p.253-254

Manasanch, Elisabet E.

2017

Volltextzugriff (PDF)

Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma

Leukemia & lymphoma, 2014-06, Vol.55 (6), p.1402-1403

2014

Volltextzugriff (PDF)

Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield

Leukemia & lymphoma, 2020-07, Vol.61 (8), p.1777-1779

2020

Volltextzugriff (PDF)

1 – 25 von 190

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(183)
Mit Volltextzugriff
(162)

Publikationsform

Artikel
(188)
Berichte
(2)

Sprache

Englisch
(190)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Gefitinib and Erlotinib in Metastatic Non‐Small Cell Lung Cancer: A Meta‐Analysis of Toxicity and Efficacy of Randomized Clinical Trials

Acetyl-CoA Synthetase 2: A Critical Linkage in Obesity-Induced Tumorigenesis in Myeloma

Proteasome inhibitors in cancer therapy

Personalized neoantigen vaccines as early intervention in untreated patients with lymphoplasmacytic lymphoma: a non-randomized phase 1 trial

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms

Phase I/Ib study of carfilzomib and panobinostat with or without dexamethasone in patients with relapsed/refractory multiple myeloma

The role of soluble B cell maturation antigen as a biomarker in multiple myeloma

Carfilzomib boosted combination therapy for relapsed multiple myeloma

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis

What to do with minimal residual disease testing in myeloma

High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications

A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis

The proteasome: mechanisms of biology and markers of activity and response to treatment in multiple myeloma

Targeted single-cell proteomic analysis identifies new liquid biopsy biomarkers associated with multiple myeloma

Response-adapted approach in newly diagnosed myeloma: when less is at least equal

Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up

The benefits of early intervention using lenalidomide for high-risk smoldering multiple myeloma: emerging data and its promising clinical impact

Myc is also the bad guy in myeloma

Whole-genome sequencing reveals progressive versus stable myeloma precursor conditions as two distinct entities

Recommend maintenance therapy with lenalidomide in multiple myeloma

Smoldering multiple myeloma: special considerations surrounding treatment on versus off clinical trials

Pre-transplant bone marrow myeloma cells: less is better

Lack of MYD88 L265P in non-immunoglobulin M lymphoplasmacytic lymphoma

Exhausted and outnumbered: CD4+ T cells in the myeloma battlefield

Suchergebnisse filtern